» Articles » PMID: 30096565

Photosensitizer-crosslinked In-situ Polymerization on Catalase for Tumor Hypoxia Modulation & Enhanced Photodynamic Therapy

Overview
Journal Biomaterials
Date 2018 Aug 11
PMID 30096565
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor hypoxia is known to be one of critical factors that aggravate the tumor resistance to photodynamic therapy (PDT) in which oxygen is essential for tumor destruction. Herein, catalase, an enzyme to trigger hydrogen peroxide (HO) decomposition, is modified by in-situ free radical polymerization, using meso-tetra(p-hydroxyphenyl) porphine (THPP) as the cross-linker to enable condensed grafting of short polyethylene glycol (PEG) chains on the protein surface as a permeable brush-like safeguard. The formulated catalase-entrapped nanocapsules (CAT-THPP-PEG) with enhanced enzyme stability can be labeled with Tc, a radioisotope ion that is chelated by the porphyrin structure of THPP, to allow in vivo single-photon emission computed tomography (SPECT) imaging. It is found that such CAT-THPP-PEG nanoparticles exhibit efficient tumor passive retention after intravenous injection, and are able to greatly relieve tumor hypoxia by triggering the decomposition of tumor endogenous HO into oxygen. With THPP functioning as a photosensitizer, in vivo PDT is further conducted, achieving a remarkable antitumor therapeutic effect. This work presents an enzyme modification strategy by in-situ polymerization with photosensitizer as the cross-linker to develop multifunctional nano-theranostics with strengthened enzymatic stability, efficient tumor passive homing, SPECT imaging capability, enhanced PDT efficacy as well as decreased immunogenicity, promising for clinical translation.

Citing Articles

pH-Activated Nanoplatform Derived from M1 Macrophages' Exosomes for Photodynamic and Ferroptosis Synergistic Therapy to Augment Cancer Immunotherapy.

Guo Y, Qian R, Wei X, Yang C, Cao J, Hou X Biomater Res. 2025; 29:0153.

PMID: 40051791 PMC: 11883086. DOI: 10.34133/bmr.0153.


Enzyme-loaded manganese-porphyrin metal-organic nanoframeworks for oxygen-evolving photodynamic therapy of hypoxic cells.

Qiao Y, Tang X, Qiuju X, Zhang G Heliyon. 2024; 10(13):e33902.

PMID: 39071555 PMC: 11282992. DOI: 10.1016/j.heliyon.2024.e33902.


Biochemical hallmarks-targeting antineoplastic nanotherapeutics.

Han J, Dong H, Zhu T, Wei Q, Wang Y, Wang Y Bioact Mater. 2024; 36:427-454.

PMID: 39044728 PMC: 11263727. DOI: 10.1016/j.bioactmat.2024.05.042.


Innovative Formulation Platform: Paving the Way for Superior Protein Therapeutics with Enhanced Efficacy and Broadened Applications.

Cao Z, Liu C, Wen J, Lu Y Adv Mater. 2024; 36(41):e2403116.

PMID: 38819929 PMC: 11571700. DOI: 10.1002/adma.202403116.


Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform.

Guo Q, Wang S, Xu R, Tang Y, Xia X RSC Adv. 2024; 14(15):10608-10637.

PMID: 38567339 PMC: 10985588. DOI: 10.1039/d4ra01026d.